Abbott Laboratories (ABT)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$108.33-0.42%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · ABT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks ABT against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 100% of the last 8 guided quarters · 15.6% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to achieve full-year 2026 comparable sales growth guidance of 6.5% to 7.5%, including growth across Diagnostics, Medical Devices, and Established Pharmaceuticals segments.
Stated as a priority in 6 of last 6 quarters. Abbott reaffirmed full-year 2026 comparable sales growth guidance of 6.5% to 7.5% in 2026-Q2 and 2026-Q1, consistent with prior 2025 guidance ranges of 7.5% to 8.0% organic growth. The reported revenue grew from $44.3B in 2025 to $12.6B in 2026-Q2 quarterly sales, reflecting ongoing growth momentum. The trajectory matches management's stated growth target, delivering consistent progress.
“Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%.”
“Abbott projects full-year 2026 comparable sales growth of 6.5% to 7.5%.”
“Abbott projects full-year 2026 organic sales growth to be in the range of 6.5% to 7.5%.”
“Abbott reaffirms previously provided full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales.”
“Abbott projects full-year 2025 organic sales growth, excluding COVID-19 testing-related sales, to be 7.5% to 8.0%.”
“Abbott projects full-year 2025 organic sales growth to be in the range of 7.5% to 8.5%.”
Continue to deliver adjusted diluted earnings per share growth with raised full-year 2026 guidance range to $5.45 to $5.60.
Stated as a priority in 6 of last 6 quarters. Abbott raised full-year 2026 adjusted diluted EPS guidance from $5.38-$5.58 in 2026-Q1 to $5.45-$5.60 in 2026-Q2. Prior 2025 guidance ranged from $5.05 to $5.25 narrowing to $5.12 to $5.18. Diluted EPS excluding specified items grew from $5.15 in 2025 to projected $5.525 midpoint in 2026, showing delivering trajectory consistent with guidance.
Capture at least $100 million in annual pre-tax synergies by 2028 from the acquisition of Exact Sciences completed in March 2026.
Stated as a priority in 3 of last 3 quarters since acquisition completion in 2026-Q1. Abbott completed acquisition of Exact Sciences in March 2026 and targets at least $100 million in annual pre-tax synergies by 2028. The synergy target is a multi-year goal with limited financial impact reported so far, indicating early stage of realization.
“Abbott completed the acquisition of Exact Sciences on March 23, 2026.”
Advance new product launches and obtain regulatory approvals, including for pulsed field ablation systems, glucose-ketone sensors, and left atrial appendage devices.
Stated as a priority in 4 of last 4 quarters. Abbott has advanced multiple new products including CE Mark for Libre Duo sensor and FDA submission for Amulet 360 device in 2026-Q2, and FDA approval of Tendyne system in 2025-Q2. These regulatory milestones and clinical data presentations demonstrate ongoing pipeline expansion and regulatory progress.
“Abbott secured CE Mark for Libre Duo, the world's first dual glucose-ketone biowearable sensor.”
Continue to increase quarterly dividend payout, maintaining status as a Dividend Aristocrat with 54 consecutive years of increases.
Stated as a priority in 6 of last 6 quarters. Abbott has consistently increased its quarterly dividend from $0.59 per share in early 2025 to $0.63 per share in 2026-Q2, maintaining 54 consecutive years of dividend increases and membership in the S&P 500 Dividend Aristocrats. The trajectory is delivering consistent dividend growth.
Over the trailing year it converted 1.30x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Not enough signal yet.
Not enough signal to read sensitivity to the US dollar, the broad stock market, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
11 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60.”
“Abbott projects full-year 2026 adjusted diluted EPS of $5.38 to $5.58.”
“Abbott projects full-year 2026 adjusted diluted EPS of $5.55 to $5.80, which reflects 10 percent growth at the midpoint.”
“Abbott reaffirms the midpoint of previously provided full-year 2025 adjusted diluted EPS guidance range and narrows the range to $5.12 to $5.18.”
“Abbott projects full-year 2025 adjusted diluted EPS of $5.10 to $5.20.”
“Abbott projects full-year 2025 adjusted diluted EPS of $5.05 to $5.25.”
“Abbott completed acquisition of Exact Sciences, establishing Abbott as a leader in oncology diagnostics.”
“At least $100 million in annual pre-tax synergies by 2028 from Exact Sciences acquisition.”
“Abbott completed submission to FDA seeking approval for Amulet 360 left atrial appendage device.”
“Abbott announced positive early results from VERITAS study on Amulet 360 LAA Occluder.”
“Abbott announced FDA approval of Tendyne transcatheter mitral valve replacement system.”
“Abbott declared quarterly dividend of $0.63 per share, 54 consecutive years of increases.”
“Abbott declared quarterly dividend of $0.63 per share, 54 consecutive years of increases.”
“Abbott declared quarterly dividend of $0.63 per share, 54 consecutive years of increases.”
“Abbott declared quarterly dividend of $0.59 per share, 53 consecutive years of increases.”
“Abbott declared quarterly dividend of $0.59 per share, 53 consecutive years of increases.”
“Abbott declared quarterly dividend of $0.59 per share, 53 consecutive years of increases.”